HC Wainwright Forecasts enGene's Q2 Earnings (NASDAQ:ENGN)

enGene Holdings Inc. (NASDAQ:ENGN - Free Report) - HC Wainwright lowered their Q2 2025 earnings per share estimates for enGene in a research report issued on Tuesday, March 11th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings per share of ($0.60) for the quarter, down from their prior estimate of ($0.44). HC Wainwright has a "Buy" rating and a $25.00 price objective on the stock. The consensus estimate for enGene's current full-year earnings is ($1.56) per share. HC Wainwright also issued estimates for enGene's Q3 2025 earnings at ($0.63) EPS, Q4 2025 earnings at ($0.65) EPS, FY2026 earnings at ($2.16) EPS, FY2027 earnings at ($1.93) EPS, FY2028 earnings at ($0.96) EPS and FY2029 earnings at ($0.15) EPS.

ENGN has been the topic of a number of other reports. Citizens Jmp upgraded shares of enGene to a "strong-buy" rating in a research note on Monday, November 18th. Morgan Stanley cut their price objective on shares of enGene from $37.00 to $34.00 and set an "overweight" rating on the stock in a research note on Tuesday. JMP Securities restated a "market outperform" rating and set a $18.00 price objective on shares of enGene in a research note on Monday, December 23rd. UBS Group cut shares of enGene from a "buy" rating to a "neutral" rating and cut their price objective for the company from $34.00 to $7.00 in a research note on Friday, February 14th. Finally, Raymond James began coverage on enGene in a report on Wednesday, November 27th. They set an "outperform" rating and a $23.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $25.22.

Remove Ads

enGene Price Performance

Shares of NASDAQ ENGN opened at $5.29 on Thursday. enGene has a fifty-two week low of $4.42 and a fifty-two week high of $18.40. The firm's 50-day simple moving average is $6.59 and its 200 day simple moving average is $7.13. The company has a quick ratio of 16.87, a current ratio of 16.87 and a debt-to-equity ratio of 0.08. The stock has a market cap of $269.67 million, a P/E ratio of -9.12 and a beta of -0.61.

enGene (NASDAQ:ENGN - Get Free Report) last posted its earnings results on Thursday, December 19th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.06.

Institutional Investors Weigh In On enGene

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Wolverine Asset Management LLC bought a new position in enGene in the 3rd quarter worth approximately $37,000. Point72 Asset Management L.P. increased its position in enGene by 1,410.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company's stock worth $4,376,000 after buying an additional 619,100 shares during the period. Franklin Resources Inc. increased its position in enGene by 48.7% in the 3rd quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company's stock worth $7,854,000 after buying an additional 389,918 shares during the period. Vontobel Holding Ltd. bought a new position in enGene in the 4th quarter worth approximately $69,000. Finally, Blue Owl Capital Holdings LP increased its position in enGene by 3.3% in the 4th quarter. Blue Owl Capital Holdings LP now owns 3,159,975 shares of the company's stock worth $21,014,000 after buying an additional 101,006 shares during the period. 64.16% of the stock is currently owned by institutional investors and hedge funds.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.